B
Ben van Baelen
Researcher at Tibotec
Publications - 9
Citations - 947
Ben van Baelen is an academic researcher from Tibotec. The author has contributed to research in topics: Population & Darunavir. The author has an hindex of 7, co-authored 7 publications receiving 806 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
Annalene Nel,Neliëtte van Niekerk,Saidi Kapiga,Linda-Gail Bekker,Cynthia Gama,Katherine Gill,Anatoli Kamali,Philip Kotze,Cheryl Louw,Zonke Mabude,Nokuthula Miti,Sylvia Kusemererwa,Hugo Tempelman,Hannelie Carstens,Brid Devlin,Michelle Isaacs,Mariëtte Malherbe,Winel Mans,Jeremy Nuttall,Marisa Russell,Smangaliso Ntshele,Marlie Smit,Leonard Solai,Patrick Spence,John Steytler,Kathleen Windle,Maarten Borremans,Sophie Resseler,Jens Van Roey,Wim Louis Julien Parys,Tony Vangeneugden,Ben van Baelen,Zeda F. Rosenberg,Ring Study Team +33 more
TL;DR: Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.
Journal ArticleDOI
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Graham R. Foster,Christophe Hézode,Jean-Pierre Bronowicki,Giampiero Carosi,Ola Weiland,Lieselotte Verlinden,Rolf van Heeswijk,Ben van Baelen,Gaston Picchio,Maria Beumont +9 more
TL;DR: Telaprevir monotherapy for 2 weeks reduces levels of HCV RNA in patients with chronic HCV genotype 2 infections, but has limited activity in patientsWith chronic hepatitis C virus genotype 3, the incidence of adverse events was similar among groups.
Journal ArticleDOI
Resistance Profile of Darunavir : Combined 24-Week Results from the POWER Trials
Sandra De Meyer,Tony Vangeneugden,Ben van Baelen,Els De Paepe,Herwig Van Marck,Gaston Picchio,Eric Lefebvre,Marie-Pierre de Béthune +7 more
TL;DR: In this population of treatment-experienced patients, darunavir/r demonstrated significantly greater efficacy than investigator-selected control PIs of trials POWER 1 and 2, regardless of baseline viral genotype or phenotype, while exhibiting a high genetic barrier to the development of resistance.
Journal ArticleDOI
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
Richard Haubrich,Daniel S Berger,Philippe Chiliade,Amy E. Colson,Marcus A. Conant,Joel E. Gallant,Timothy J. Wilkin,Jeffrey P. Nadler,Gerald Pierone,Michael S. Saag,Ben van Baelen,Eric Lefebvre +11 more
TL;DR: TMC114/r treatment resulted in greater virological and immunological responses in ART-experienced patients compared with CPI at 24 weeks, and more patients in each TMC 114/r dose group achieved ≥ 1.0 log10 copies/ml reduction in HIV-1 RNA than in the CPI group.
Journal ArticleDOI
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
Sandra De Meyer,Erkki Lathouwers,Inge Dierynck,Els De Paepe,Ben van Baelen,Tony Vangeneugden,Sabrina Spinosa-Guzman,Eric Lefebvre,Gaston Picchio,Marie-Pierre de Béthune +9 more
TL;DR: In treatment-experienced, LPV-naive patients, the overall virologic failure rate in the DRV/r arm was low and was associated with limited resistance development, showing that the use of DRv/r in earlier lines of treatment was less likely to lead to cross-resistance to other protease inhibitors compared with LPV/ r.